Develops spherical nucleic acid (SNA) technology for immunotherapy and other therapeutic applications.
Exicure, Inc. is a pioneering biotechnology company headquartered in Chicago, Illinois, specializing in the development of innovative therapies using its proprietary spherical nucleic acid (SNA) technology. This cutting-edge platform enables the company to target neurological disorders and hair loss with unprecedented precision and efficacy. At the forefront of its pipeline is SCN9A, a promising candidate undergoing preclinical studies for the treatment of neuropathic and chronic pain, highlighting Exicure's commitment to addressing significant medical challenges.
In collaboration with AbbVie Inc., Exicure has entered into a strategic agreement to develop SNA-based treatments specifically designed for hair loss disorders. This partnership underscores the company's strategic approach to leveraging its technology for dermatological applications, aiming to revolutionize treatments in this field. Additionally, Exicure has partnered with Ipsen S.A. to advance research, development, and commercialization efforts focused on novel spherical nucleic acids targeting Huntington's disease and Angelman syndrome, further expanding its therapeutic reach.
Founded in 2011, Exicure continues to drive innovation in biotechnology through its pioneering SNA platform. With a strong focus on advancing therapeutic options and strategic collaborations with industry leaders, the company is poised to make significant strides in improving patient outcomes across neurological and dermatological conditions worldwide.